Debridement and placement dressings for thick exudate and instillation
By designing a multi-layer dressing system that combines negative pressure and infusion solution, the problem of insufficient wound care efficiency in existing technologies has been solved, achieving efficient wound cleaning and rapid healing.
Patent Information
- Application Number
- CN202611236954.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-06-05
- Filing Date
- 2019-01-03
- Publication Date
- 2026-11-10
AI Technical Summary
There is room for improvement in existing negative pressure and infusion therapy systems for wound care, particularly in their inefficiency in improving tissue growth rate and cleaning wounds.
A dressing system has been designed, comprising a porous manifold material layer, a perforated polymer layer, and a hydrophobic gel layer, which optimizes the therapeutic effect on tissue sites through a combination of negative pressure and infusion solution. This dressing system, including a porous manifold layer, a polymer membrane layer, and an expandable fluid confinement section, combined with a negative pressure source and an infusion solution source, achieves efficient wound cleaning and promotes tissue growth.
The synergistic effect of negative pressure and infusion solution significantly improves wound cleaning efficiency and tissue growth rate, shortens healing time, and reduces the frequency of dressing changes.
Smart Images

Figure CN123058892A_ABST
Abstract
Description
[0001] This application is a divisional application of the application filed on January 3, 2019, with application number 201980010973.4 and invention title "Dressing for Removing and Placing Thick Exudates and Drips".
[0002] Related applications This application claims the following benefits under 35 USC § 119(e): International Patent Application No. PCT / US2018 / 035968, filed June 5, 2018, entitled "Peel and Place Dressing for Thick Exudate and Instillation"; U.S. Patent Application No. 15 / 997,833, filed June 5, 2018, entitled "Peel and Place Dressing for Thick Exudate and Instillation"; and Peel and Place Dressing for Thick Exudate and Instillation, filed January 4, 2018. The U.S. Provisional Patent Application Serial No. 62 / 613,494, entitled “INSTILLATION”, is incorporated herein by reference for all purposes. Technical Field
[0003] The invention set forth in the appended claims relates generally to tissue treatment systems, and more specifically, but not in a limiting way, to systems, apparatus, and methods for treating tissues in a negative pressure therapy environment. background Clinical research and practice have shown that reducing pressure near tissue sites can promote and accelerate the growth of new tissue at those sites. This phenomenon has many applications, but it has proven particularly beneficial in wound treatment. Regardless of whether the wound is caused by trauma, surgery, or other factors, proper wound care is crucial for outcome. The use of pressure reduction to treat wounds or other tissues is commonly referred to as "negative pressure therapy," but it also has other names, including "negative pressure wound therapy," "decompression therapy," "vacuum therapy," "vacuum-assisted closure," and "local negative pressure." Negative pressure therapy can provide many benefits, including the migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissues at the wound site. These benefits can collectively enhance granulation tissue development and shorten healing time.
[0004] It is also widely accepted that cleaning tissue sites is highly beneficial for new tissue growth. For example, a liquid solution can be used to rinse a wound, or a liquid solution can be used to clean cavities for therapeutic purposes. These practices are often referred to as “irrigation” and “cleaning,” respectively. “Infusion” is another practice, which generally refers to the process of slowly introducing a fluid into a tissue site and retaining the fluid for a specified period of time before removing it. For example, infusing a local treatment solution into a wound bed can be combined with negative pressure therapy to further promote wound healing by diluting soluble contaminants in the wound bed and removing infectious material. As a result, the burden of soluble bacteria can be reduced, contaminants can be removed, and the wound can be cleaned.
[0005] While the clinical benefits of negative pressure therapy and / or infusion therapy are well known, improvements in therapy systems, components, and processes can benefit both healthcare providers and patients. Summary of the Invention
[0006] The appended claims set forth novel and useful systems, apparatus, and methods for treating tissues in a negative pressure therapy environment. Illustrative embodiments are also provided to enable those skilled in the art to make and use the claimed subject matter.
[0007] For example, in some embodiments, a dressing for treating tissue may include a first layer of porous manifolded material. In some examples, the first layer may be formed of a mesh foam. A series of pores may be formed in the first layer. In some examples, the diameter of the pores may be from about 2 mm to about 10 mm, and in some examples, the center-to-center spacing may be from about 2 mm to about 10 mm. A second layer may be arranged adjacent to the first layer. The second layer may be formed of a perforated polymer. Hydrophobic polymers may be advantageous in some embodiments. A thickness of 25 to 50 micrometers may be suitable for some embodiments of the second layer. In some embodiments, the perforations may be slots. In some examples, the width of the slots may be between 0.5 mm and 2 mm, and in some examples, the length may be from about 3 mm to about 5 mm. The perforations may or may not be aligned with the pores in the first layer. The perforations may be elongated or cross-shaped windows aligned with or aligned with the pores, and these perforations may serve as flaps to prevent granulation tissue from contacting the sides of the pores. The second layer is generally oriented towards the tissue site. The dressing may optionally include a third layer formed of a soft polymer. The soft polymer can be, for example, a silicone gel. In some configurations, a coating weight of approximately 450 grams per square meter may be suitable for a silicone gel. Other exemplary polymers that may be suitable include polyurethanes, hydrocolloids, and acrylic compounds. The third layer may also have perforations or pores. The third layer is typically oriented towards the tissue site and may be arranged adjacent to the first layer, such that the first layer is disposed between the third layer and the first layer. The perforations or pores in the third layer may be aligned with one or more perforations in the first layer. Aligning or aligning the perforations can reduce the pressure drop effect of thick exudates and allow the infusion solution to move rapidly through the dressing to reach the tissue. In some embodiments, the size of the perforations and pores in the first and third layers may vary depending on their location. For example, smaller perforations toward the edge of the dressing can guide the infusion solution toward the central portion of the dressing and away from the periphery of the dressing.
[0008] More generally, a device for treating tissue sites with negative pressure can be a dressing comprising a first and a second layer arranged adjacent to each other in a stacked relationship, and a cover disposed on the first layer. The first layer may include a manifold having a plurality of through-holes, and the second layer may include a polymer membrane having a plurality of fluid constrictions configured to expand in response to a pressure gradient on the polymer membrane. In some examples, the cover may include or be substantially composed of a polymer cover cloth. In some embodiments, each of the plurality of through-holes may have an effective diameter between about 2 mm and about 10 mm, and their centers may be spaced between about 2 mm and about 10 mm apart. In some embodiments, the through-holes may be arranged in an array. The through-holes may be offset from or aligned with at least some of the fluid constrictions.
[0009] Additionally, in some embodiments, the dressing may include a third layer. The third layer may be arranged adjacent to the second layer and may comprise or consist substantially of a gel layer having multiple pores. In some embodiments, the gel layer may be hydrophobic. A polymeric gel having a coating weight of approximately 250 grams per square centimeter may be suitable for some embodiments of the third layer.
[0010] In some examples, the dressing may include a retaining layer disposed between the cover and the first layer. In more specific examples, the retaining layer may include or be substantially composed of a manifold arranged adjacent to or consisting of a through-hole in the first layer. In some embodiments, the retaining layer may have greater compressibility than the first layer.
[0011] Alternatively or concurrently, in some embodiments, the first layer may include a boundary and an interior. In some examples, vias may be excluded from the boundary. In other examples, vias in the boundary may be smaller than vias in the interior.
[0012] In some examples, the first layer may include a manifold with variable density. The variable density can be formed by a first region having a first density and a second region having a second density. For example, the first region may include a first material with a density greater or less than that of the material in the second region. In some examples, the first and second regions may include the same material or materials with similar densities, and at least one of the first or second regions may be processed to change the density of the material.
[0013] This application provides the following: 1) A dressing for treating tissue sites using negative pressure, said dressing comprising: The first layer includes a manifold having multiple through holes; A second layer adjacent to the first layer, the second layer comprising a polymer membrane having a plurality of fluid confinement portions configured to expand in response to a pressure gradient on the polymer membrane; and The cover adjacent to the first layer comprises a polymer cover fabric.
[0014] 2) The dressing as described in 1), wherein each of the plurality of through holes has an effective diameter of at least 2 mm.
[0015] 3) The dressing as described in 1), wherein each of the plurality of through holes has an effective diameter of not more than 10 mm.
[0016] 4) The dressing as described in 1), wherein each of the plurality of through holes has an effective diameter between about 2 mm and about 10 mm.
[0017] 5) The dressing as described in any one of 1) to 4), wherein the centers of the plurality of through holes are spaced about 2 mm apart.
[0018] 6) The dressing as described in any one of 1) to 4), wherein the centers of the plurality of through holes are spaced about 10 mm apart.
[0019] 7) The dressing as described in any one of 1) to 4), wherein the centers of the plurality of through holes are spaced between about 2 mm and about 10 mm apart.
[0020] 8) The dressing as described in any of the preceding claims, wherein the plurality of through holes are formed in an array.
[0021] 9) The dressing as described in any of the preceding claims, wherein the through-hole is offset from the fluid confinement portion.
[0022] 10) The dressing as described in any of the preceding claims, wherein at least some of the through holes are aligned with at least some of the fluid restricting portions.
[0023] 11) The dressing as described in any of the preceding claims, wherein the manifold comprises a mesh foam.
[0024] 12) The dressing as described in 1), wherein the manifold comprises compressed mesh foam.
[0025] 13) The dressing as described in 1), wherein the manifold comprises felted mesh foam.
[0026] 14) The dressing as described in any of the preceding claims, wherein the polymer film of the second layer is hydrophobic.
[0027] 15) The dressing as described in 14), wherein the polymer film of the second layer is polyethylene.
[0028] 16) The dressing as described in 14), wherein the polymer film is a polyethylene film with an area density of less than 30 grams per square meter.
[0029] 17) The dressing as described in any one of 1) to 16), wherein the fluid restrictor comprises a plurality of slots, each slot having a length of less than 5 mm.
[0030] 18) The dressing as described in any one of 1) to 16), wherein the fluid restrictor includes a plurality of slots, each slot having a width of less than 2 mm.
[0031] 19) The dressing as described in any one of 1) to 16), wherein the fluid restrictor comprises a plurality of slots, each slot having a length of less than 4 mm and a width of less than 2 mm.
[0032] 20) The dressing as described in any of the preceding claims, wherein the fluid restrictor comprises, or is substantially composed of, an elastomeric valve in the polymer film, and the elastomeric valve is normally closed.
[0033] 21). The dressing as described in any one of 1) to 16), wherein the fluid constriction portion includes a window in the polymer film.
[0034] 22). The dressing as described in 21), wherein the fluid constriction portion includes a slit in the polymer film.
[0035] 23). The dressing as described in 21), wherein the fluid constriction portion includes intersecting slits in the polymer film.
[0036] 24). The dressing as described in 21), wherein the fluid restrictor includes a flap configured to open at least partially into the through-hole under negative pressure.
[0037] 25) The dressing as described in any of the preceding claims, wherein the cover includes an edge extending beyond the first layer and the second layer, and an adhesive disposed in the edge.
[0038] 26) The dressing as described in any of the preceding claims further includes a third layer arranged adjacent to the second layer, the third layer comprising a gel having a plurality of pores.
[0039] 27) The dressing as described in 26), wherein the gel of the third layer is a polymeric gel having a coating weight of about 250 grams per square centimeter.
[0040] 28). The dressing as described in 26), wherein the gel of the third layer is a silicone gel.
[0041] 29) The dressing as described in 26), wherein the gel of the third layer comprises a silicone gel having a coating weight of about 250 grams per square centimeter.
[0042] 30) The dressing as described in 26), wherein the gel is silicone, polyurethane, hydrocolloid, or acrylic compound.
[0043] 31). The dressing as described in 26), wherein the plurality of pores in the third layer have an effective diameter of about 2 mm to about 5 mm.
[0044] 32). The dressing as described in 26), wherein the first layer and the second layer are encapsulated between the third layer and the cover.
[0045] 33) The dressing as described in 26), wherein at least some of the plurality of holes are aligned with at least some of the fluid restricting portions.
[0046] 34). The dressing as described in 26), wherein the through hole is aligned with the fluid confinement portion and the plurality of holes.
[0047] 35) The dressing as described in 26) wherein the average length of the fluid confinement portion does not significantly exceed the average size of the orifice.
[0048] 36). The dressing as described in 26), wherein the orifice limits the effective size of the fluid confinement portion.
[0049] 37) The dressing as described in 26), wherein the size of each of the holes is determined to expose no more than two of the fluid confinement portions.
[0050] 38) The dressing as described in any of the preceding claims, wherein the polymer film does not extend into the through-hole.
[0051] 39) The dressing as described in any of the preceding claims, wherein the polymer film does not extend beyond the through-hole.
[0052] 40) The dressing as described in any of the preceding claims further includes a fluid port coupled to the cover, the fluid port being configured to be coupled to a fluid conductor.
[0053] 41) The dressing as described in any of the preceding claims further includes a retaining layer disposed between the first layer and the cover.
[0054] 42). The dressing as described in 41), wherein the retaining layer includes a second manifold arranged adjacent to the through-hole.
[0055] 43). The dressing as described in 41), wherein the retaining layer comprises open-cell foam.
[0056] 44). The dressing as described in 41), wherein the retaining layer has greater compressibility than the first layer.
[0057] 45) The dressing as described in 41), wherein the retaining layer comprises an open-cell foam having between 10 and 80 pores per inch.
[0058] 46) The dressing as described in any of the preceding claims, wherein the first layer includes a boundary without through holes.
[0059] 47). The dressing as described in any of the preceding items, wherein: The first layer includes the boundary and the interior; At least some of the through holes are arranged in the boundary and have a first width; At least some of the through holes are arranged in the interior and have a second width; and The first width is smaller than the second width.
[0060] 48). A dressing for treating tissue sites using negative pressure, said dressing comprising: The first layer includes a manifold with variable density; A second layer adjacent to the first layer, the second layer comprising a polymer membrane having a plurality of fluid confinement portions configured to expand in response to a pressure gradient on the polymer membrane; and The cover adjacent to the first layer comprises a polymer cover fabric.
[0061] 49) The dressing as described in 48), wherein the manifold includes a first region having a first density and a second region having a second density.
[0062] 50) The dressing as described in 49), wherein the first region comprises a first material and the second region comprises a second material.
[0063] 51). The dressing as described in 48), wherein the manifold comprises a pattern of regions with different densities.
[0064] 52). The dressing as described in 51), wherein the pattern is an array.
[0065] 53). The dressing as described in 52), wherein the area is rectangular.
[0066] 54). The dressing as described in 51), wherein the pattern comprises concentric rings.
[0067] 55). The dressing as described in any one of 48) to 54), wherein the manifold comprises open-cell foam.
[0068] 56). A system for treating tissues using negative pressure, the system comprising: Negative pressure source; and The dressing according to any one of 1) to 55) is fluidly connected to the negative pressure source.
[0069] 57). The system as described in 56) further includes a drip solution source fluidly connected to the dressing.
[0070] 58). A method for treating wounds using negative pressure, the method comprising: The dressing according to any one of 1) to 55) is applied to the wound; Fluidly connect the negative pressure source to the dressing; and The therapeutic level of negative pressure from the negative pressure source is delivered to the dressing.
[0071] 59). The method described in 58) further includes: Fluidly connect the infusion solution source to the dressing; and The solution from the drip solution source is delivered to the dressing.
[0072] 60) The method as described in 58) or 59), wherein applying the dressing includes sealing the dressing onto the epidermis adjacent to the wound.
[0073] 61). The method of any one of 58) to 60), wherein applying the dressing comprises placing at least a portion of the dressing on the edge of the wound.
[0074] 62). The method of any one of 58) to 61), wherein the wound is a surface wound.
[0075] 63). The method of any one of 58) to 62), wherein the dressing is retained on the wound for at least 7 days.
[0076] 64) Use of any of the dressings, systems, or methods described in any of the preceding claims for the treatment of tissue sites.
[0077] 65) Use of any of the dressings, systems, or methods described in any of the preceding claims for the treatment of wounds.
[0078] 66) Use of any of the dressings, systems, or methods described in any of the preceding claims for the purpose of treating a wound continuously for at least 7 days without changing the dressing.
[0079] 67) Systems, apparatus and methods substantially as described herein.
[0080] The purpose, advantages, and preferred methods of making and using the claimed subject matter can be best understood by referring to the accompanying drawings and the following detailed description of illustrative embodiments. Attached Figure Description
[0081] Figure 1 This is a functional block diagram of an exemplary embodiment of a therapeutic system that can provide negative pressure therapy and infusion therapy according to this specification; Figure 2 It's a line graph, showing what can be compared to... Figure 1 Additional details regarding exemplary pressure control modes associated with some embodiments of the therapeutic system; Figure 3 It's a line graph, showing what can be compared to... Figure 1 Additional details associated with another exemplary pressure control mode in some embodiments of the therapeutic system; Figure 4 It is possible to be with Figure 1 An assembly view of an example dressing associated with some embodiments of the therapeutic system; Figure 5 It is possible to be with Figure 4 A schematic diagram illustrating examples of the layers associated with some embodiments of the dressing; Figure 6 It is possible to be with Figure 1 An assembly view of another example of the dressing associated with some embodiments of the therapeutic system; Figure 7 It is possible to be with Figure 6 A schematic diagram of exemplary configurations of pores associated with some embodiments of layers in a dressing; Figure 8 yes Figure 7 Exemplary layers superimposed on Figure 5 A schematic diagram on an exemplary layer; Figure 9 It is possible to be with Figure 1 A top view of another example of the layer associated with some embodiments of the dressing; Figure 10 and Figure 11 It shows that it can be used with Figure 1 Other exemplary configurations of valves associated with the various layers of the dressing; Figure 12 yes Figure 1 A cross-sectional schematic diagram of an example dressing; Figure 13 yes Figure 1 A cross-sectional schematic diagram of another example of dressing; Figure 14It is perforated and can be used with Figure 1 A plan view of an example of a manifold layer associated with some embodiments of the dressing; Figure 15 and Figure 16 It is possible to be with Figure 1 Plan view of some embodiments of the dressing and other examples of perforations in the associated manifold layer; Figure 17 It is possible to be with Figure 1 A plan view of another example of a perforation in the manifold associated with some embodiments of the dressing; and Figure 18 It is possible to be with Figure 1 A top view of another example of the layer associated with some embodiments of the dressing; Figure 19 It is possible to be with Figure 1 A top view of another example of the layer associated with some embodiments of the dressing; Figure 20 It is possible to be with Figure 1 A top view of another example of the layer associated with some embodiments of the dressing; Figure 21 yes Figure 1 An assembled view of another example of the dressing, showing additional details that can be associated with some embodiments; and Figure 22 It's a flowchart that shows what can be done with... Figure 1 Details related to exemplary operating methods of the therapeutic system. Detailed Implementation
[0082] The following description of exemplary embodiments provides information that enables those skilled in the art to make and use the subject matter set forth in the appended claims, but some details already well known in the art may be omitted. Therefore, the following detailed description should be understood as illustrative rather than restrictive.
[0083] This document may also describe these exemplary embodiments with reference to the spatial relationships or spatial orientations of the different elements depicted in the accompanying drawings. Generally, such relationships or orientations assume a reference frame consistent with or relative to the patient in the position to be treated. However, those skilled in the art should recognize that this reference frame is merely a descriptive and appropriate measure, and not a strict specification.
[0084] Figure 1 This is a simplified functional block diagram of an exemplary embodiment of a therapy system 100 that can provide negative pressure therapy and local treatment solution infusion to tissue sites according to this specification.
[0085] In this context, the term "tissue site" broadly refers to a wound, defect, or other therapeutic target located on or within tissue, including but not limited to bone, adipose tissue, muscle tissue, nerve tissue, skin tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. Wounds can include, for example, chronic, acute, traumatic, subacute, and laceration wounds, partial skin burns, ulcers (such as diabetic ulcers, pressure ulcers, or venous insufficiency ulcers), flaps, and grafts. The term "tissue site" can also refer to any area of tissue that is not necessarily injured or defective, but rather an area in which the growth of additional tissue may be desired or beneficial. For example, negative pressure can be applied to a tissue site to grow additional tissue that can be harvested and transplanted.
[0086] For example, the therapy system 100 may include a negative pressure source or supply source (e.g., negative pressure source 105), a dressing 110, a fluid container (e.g., container 115), and a regulator or controller (e.g., controller 120). Additionally, the therapy system 100 may include sensors for measuring operating parameters and providing feedback signals indicative of these operating parameters to the controller 120. Figure 1 As shown, for example, the therapy system 100 may include a first sensor 125 and a second sensor 130 coupled to a controller 120. (As...) Figure 1 As shown in the examples, in some embodiments, dressing 110 may include tissue interface 135, cover 140, or both or substantially thereof.
[0087] The therapeutic system 100 may also include an infusion solution source. For example, the solution source 145 may be fluidly coupled to the dressing 110, such as... Figure 1 The exemplary embodiments are illustrated below. In some embodiments, the solution source 145 may be fluidly coupled to a positive pressure source (e.g., positive pressure source 150), a negative pressure source (e.g., negative pressure source 105), or both. A regulator, such as an infusion regulator 155, may also be fluidly coupled to the solution source 145 and the dressing 110 to ensure proper delivery of the infusion solution (e.g., saline) to the tissue site. For example, the infusion regulator 155 may include a piston that can be pneumatically actuated by the negative pressure source 105 to draw the infusion solution from the solution source during a negative pressure interval and to drip the solution into the dressing during a ventilation interval. Alternatively or additionally, the controller 120 may be coupled to the negative pressure source 105, the positive pressure source 150, or both, to control the delivery of the infusion solution to the tissue site. In some embodiments, the infusion regulator 155 may also be fluidly coupled to the negative pressure source 105 via the dressing 110, such as… Figure 1 The example shown is as follows.
[0088] Some components of the therapy system 100 may be housed within or combined with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate therapy. For example, in some embodiments, the negative pressure source 105 may be combined with the solution source 145, the controller 120, and other components to form a therapy unit.
[0089] Generally, components of the therapy system 100 can be directly or indirectly coupled. For example, a negative pressure source 105 can be directly coupled to a container 115 and indirectly coupled to a dressing 110 via the container 115. In some cases, the coupling may include fluid coupling, mechanical coupling, thermal coupling, electrical coupling, or chemical coupling (such as chemical bonds), or some combination of couplings. For example, the negative pressure source 105 may be electrically coupled to a controller 120 and fluidly coupled to one or more distribution components to provide a fluid path to the tissue site. In some embodiments, components may also be coupled by means of physical proximity, integral with a single structure, or formed from the same material.
[0090] The distribution component is preferably detachable and may be disposable, reusable, or recyclable. Dressing 110 and container 115 are examples of distribution components. A fluid conductor is another illustrative example of a distribution component. In this context, "fluid conductor" broadly includes tubes, pipes, hoses, conduits, or other structures having one or more lumens or open passages adapted to deliver fluid between two ends. Typically, tubes are elongated cylindrical structures with a degree of flexibility, but their geometry and rigidity can be varied. Furthermore, some fluid conductors may be molded into other components or otherwise integrally combined with other components. The distribution component may also include or comprise interfaces or fluid ports to facilitate the attachment and disengagement of other components. In some embodiments, for example, a dressing interface may facilitate the attachment of a fluid conductor to dressing 110. For example, such a dressing interface may be the SENSAT.RAC™ pad available from Kinetic Concepts, Inc., San Antonio, Texas.
[0091] For example, a negative pressure supply source (such as negative pressure source 105) can be an air reservoir under negative pressure, or it can be a manual or electric device, such as a vacuum pump, a suction pump, a wall-mounted suction port available in many healthcare facilities, or a micropump. "Negative pressure" generally refers to a pressure less than the local ambient pressure, which is, for example, the ambient pressure in a local environment outside a sealed treatment environment. In many cases, the local ambient pressure can also be the atmospheric pressure at the location of the tissue site. Alternatively, the pressure can be less than the hydrostatic pressure associated with the tissue at the tissue site. Unless otherwise stated, the pressure values stated herein are gauge pressures. An increase in negative pressure generally refers to a decrease in absolute pressure, and a decrease in negative pressure generally refers to an increase in absolute pressure. Although the amount and nature of the negative pressure applied to the tissue site can vary depending on treatment needs, the pressure is generally a low vacuum, also commonly referred to as a rough vacuum, between -5 mm Hg (-667 Pa) and -500 mm Hg (-66.7 kPa). Common treatment ranges are between -50 mm Hg (-6.7 kPa) and -300 mm Hg (-39.9 kPa).
[0092] Container 115 represents a container, canister, pouch, or other storage component that can be used to manage exudates and other fluids aspirated from tissue sites. In many environments, rigid containers may be preferred or necessary for the collection, storage, and disposal of fluids. In other environments, fluids can be properly disposed of without the need for rigid container storage, and reusable containers can reduce waste and costs associated with negative pressure therapy.
[0093] A controller (such as controller 120) may be a microprocessor or computer programmed to operate one or more components of the therapy system 100 (such as negative pressure source 105). In some embodiments, for example, controller 120 may be a microcontroller that typically includes an integrated circuit including a processor core and memory programmed to directly or indirectly control one or more operating parameters of the therapy system 100. For example, operating parameters may include power applied to negative pressure source 105, pressure generated by negative pressure source 105, or pressure distributed to tissue interface 135. Controller 120 is also preferably configured to receive one or more input signals (such as feedback signals) and is programmed to modify one or more operating parameters based on the input signals.
[0094] Sensors, such as first sensor 125 and second sensor 130, are generally considered in the art to be any device operable to detect or measure a physical phenomenon or characteristic, and typically provide a signal indicating the detected or measured phenomenon or characteristic. For example, first sensor 125 and second sensor 130 may be configured to measure one or more operating parameters of the therapeutic system 100. In some embodiments, first sensor 125 may be a transducer configured to measure pressure in a pneumatic passage and convert the measurement into a signal indicating the measured pressure. In some embodiments, for example, first sensor 125 may be a piezoresistive strain gauge. In some embodiments, second sensor 130 may optionally measure operating parameters of the negative pressure source 105, such as voltage or current. Preferably, the signals from first sensor 125 and second sensor 130 are suitable as input signals to controller 120, but in some embodiments, some signal conditioning may be appropriate. For example, the signal may need to be filtered or amplified before being processed by controller 120. Typically, the signal is an electrical signal, but it may be represented in other forms, such as an optical signal.
[0095] The tissue interface 135 can be generally adapted to partially or completely contact the tissue site. The tissue interface 135 can take many forms and can have various sizes, shapes, or thicknesses, depending on factors such as the type of treatment being performed or the nature and size of the tissue site. For example, the size and shape of the tissue interface 135 can be adapted to the shape of deep and irregularly shaped tissue sites. Furthermore, any or all surfaces of the tissue interface 135 can have protrusions or uneven, rough, or jagged contours that may cause strain and stress in the tissue site, potentially promoting granulation tissue growth at the tissue site.
[0096] In some embodiments, the cover 140 can provide a bacterial barrier and prevent physical trauma. The cover 140 may also be made of a material that can reduce evaporation loss and provide a fluid seal between two components or two environments (e.g., between a treatment environment and a local external environment). The cover 140 may include, for example, an elastomeric membrane or film, or be composed of therein, which can provide a seal sufficient to maintain negative pressure at the tissue site for a given negative pressure source. In some applications, the cover 140 may have a high moisture vapor transmission rate (MVTR). For example, in some embodiments, the MVTR may be at least 250 g / m² per 24 hours, measured at 38°C and 10% relative humidity (RH) using the upright cup technique according to the ASTM E96 / E96M upright cup method. In some embodiments, an MVTR of up to 5,000 g / m² per 24 hours can provide effective breathability and mechanical properties.
[0097] In some exemplary embodiments, the cover 140 may be a polymer cover that is permeable to water vapor but impermeable to liquids, such as a polyurethane membrane. Such covers typically have a thickness in the range of 25 to 50 micrometers. For permeable materials, the permeability should generally be low enough to maintain the desired negative pressure. The cover 140 may include one or more of the following materials: polyurethane (PU), such as hydrophilic polyurethane; cellulose materials; hydrophilic polyamides; polyvinyl alcohol; polyvinylpyrrolidone; hydrophilic acrylic compounds; silicones, such as hydrophilic silicone elastomers; natural rubber; polyisoprene; styrene-butadiene rubber; chloroprene rubber; polybutadiene; nitrile rubber; butyl rubber; ethylene propylene diene monomer; chlorosulfonated polyethylene; polysulfide rubber; ethylene vinyl acetate (EVA); copolyesters; and polyether block polyimide copolymers. Such materials are commercially available, such as Tegaderm® cover fabric from 3M Company in Minneapolis, Minnesota; polyurethane (PU) cover fabric from Avery Dennison Corporation in Pasadena, California; polyether block polyamide copolymers (PEBAX), such as Arkema SA from Colombes, France; and Inspire 2301 and Inpsire 2327 polyurethane films from Expopack Advanced Coatings in Wrexham, United Kingdom. In some embodiments, cover 140 may include a 2600 g / m² polyurethane film. 2 / 24-hour MVTR (Upright Cup Technology) and INSPIRE 2301 with a thickness of approximately 30 microns.
[0098] An attachment device can be used to attach the cover 140 to an attachment surface, such as undamaged epidermis, a gasket, or another cover. The attachment device can take many forms. For example, the attachment device can be a medically acceptable pressure-sensitive adhesive configured to bond the cover 140 to the epidermis surrounding a tissue site. In some embodiments, for example, a portion or all of the cover 140 may be coated with an adhesive, such as an acrylic adhesive, having a coating weight between 25 and 65 grams per square meter (gsm). In some embodiments, the adhesive may be applied along the edges around the cover 140. In some embodiments, a thicker adhesive or combination of adhesives may be applied to improve sealing and reduce leakage. Other exemplary embodiments of the attachment device may include double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, or organic gel.
[0099] Solution source 145 may also represent a container, canister, pouch, bag, or other storage component that can provide a solution for infusion therapy. The composition of the solution may vary depending on the prescribed therapy, but examples of solutions suitable for some prescriptions include hypochlorite-based solutions, silver nitrate (0.5%), sulfur-based solutions, biguanide, cation solutions, and isotonic solutions.
[0100] Figure 2 This is a graph illustrating additional details of exemplary control modes that can be associated with some embodiments of controller 120. In some embodiments, controller 120 may have a continuous pressure mode in which negative pressure source 105 is operated to provide a constant target negative pressure for the duration of treatment or until manual discontinuation, as indicated by lines 205 and 210. Alternatively or concurrently, the controller may have an intermittent pressure mode, such as... Figure 2 As shown in the example. In Figure 2 In the diagram, the x-axis represents time, and the y-axis represents the negative pressure generated by the negative pressure source 105 over time. Figure 2 In the example, controller 120 can operate negative pressure source 105 to cycle between target pressure and atmospheric pressure. For example, the target pressure value can be set to 125 mmHg (as indicated by line 205) for a specified period of time (e.g., 5 minutes), followed by a specified off period of time (e.g., 2 minutes), as indicated by the gap between solid lines 215 and 220. The cycle (as indicated by line 220) can be repeated by activating negative pressure source 105, which can create a square wave pattern between target pressure and atmospheric pressure.
[0101] In some exemplary embodiments, the increase in negative pressure from ambient pressure to the target pressure may not be instantaneous. For example, the negative pressure source 105 and dressing 110 may have an initial rise time, as indicated by the dashed line 225. The initial rise time may vary depending on the type of dressing and therapeutic equipment used. For example, for one therapeutic system, the initial rise time may be in the range of about 20-30 mmHg / s, while for another therapeutic system it may be in the range of about 5-10 mmHg / s. If the therapeutic system 100 operates in intermittent mode, the repeated rise time (as indicated by the solid line 220) may be substantially equal to the value of the initial rise time (as indicated by the dashed line 225).
[0102] Figure 3 This is a graph illustrating additional details that can be associated with another exemplary pressure control mode in some embodiments of the therapy system 100. Figure 3 In the diagram, the x-axis represents time, and the y-axis represents the negative pressure generated by negative pressure source 105. Figure 3 In the example, the target pressure can vary over time in a dynamic pressure mode. For instance, the target pressure can vary in the form of a triangular waveform between a minimum and maximum negative pressure of 50-125 mmHg, wherein the rise time 305 is set at a rate of +25 mmHg / min, and the fall time 310 is set at -25 mmHg / min accordingly. In other embodiments of the therapeutic system 100, the triangular waveform can vary between a negative pressure of 25-125 mmHg, wherein the rise time 305 is set at a rate of +30 mmHg / min, and the fall time 310 is set at -30 mmHg / min.
[0103] In some embodiments, the controller 120 can control or determine a variable target pressure in a dynamic pressure mode, and the variable target pressure can vary between a maximum pressure value and a minimum pressure value, which can be set as operator-specified inputs representing a desired negative pressure range. The variable target pressure can also be processed and controlled by the controller 120, which can change the target pressure based on a predetermined waveform (e.g., a triangular waveform, a sine waveform, or a sawtooth waveform). In some embodiments, the waveform can be set by the operator to a predetermined negative pressure desired for the therapy or a negative pressure that varies over time.
[0104] Figure 4 yes Figure 1 An assembled view of an example dressing 110 shows additional details that can be associated with some embodiments where the tissue interface 135 includes more than one layer. Figure 4In the example, the tissue interface 135 includes a first layer 405 and a second layer 410. In some embodiments, the first layer 405 may be arranged adjacent to the second layer 410. For example, the first layer 405 and the second layer 410 may be stacked such that the first layer 405 is in contact with the second layer 410. In some embodiments, the first layer 405 may also be bonded to the second layer 410.
[0105] The first layer 405 typically includes a manifold or a manifold layer having multiple perforations 415, or is substantially composed of it. The first layer 405 can provide means for collecting fluid from the tissue interface 135 under pressure or for distributing fluid onto the tissue interface. For example, the first layer 405 can be adapted to receive negative pressure from a source and distribute the negative pressure onto the tissue interface 135 through multiple orifices, which can have the effect of collecting fluid from the tissue site and drawing the fluid toward the source. In some embodiments, the fluid path can be reversed, or an auxiliary fluid path can be provided to facilitate the delivery of fluid (e.g., fluid from an infusion solution source) to the tissue interface 135.
[0106] In some illustrative embodiments, the pathways of the first layer 405 may be interconnected to improve fluid distribution or collection. In some illustrative embodiments, the first layer 405 may comprise or be substantially composed of a porous material with interconnected fluid pathways. For example, open-cell foams, porous tissue aggregates, and other porous materials such as gauze or felt pads typically include pores, edges, and / or walls adapted to form interconnected fluid channels. Other suitable materials may include, for example, 3D textiles (Baltex, Muller, Heathcoates), nonwovens (Libeltex, Freudenberg), 3D polymer structures (molded polymers, embossed and molded films, and melt-bonded films [Supracore]), and meshes. Liquids, gels, and other foams may also comprise or be cured to include pores and fluid pathways. In some embodiments, the first layer 405 may additionally or alternatively include protrusions forming interconnected fluid pathways. For example, the first layer 405 may be molded to provide surface protrusions defining interconnected fluid pathways. Any or all surfaces of the first layer 405 may have non-uniform, rough, or irregular profiles.
[0107] In some embodiments, the first layer 405 may comprise or be substantially composed of a mesh foam, the pore size and free volume of which may be varied as required by the prescribed therapy. For example, a mesh foam having at least 90% free volume may be suitable for many therapeutic applications, and foams with an average pore size in the range of 400 to 600 micrometers may be particularly suitable for certain types of therapies. The tensile strength of the first layer 405 may also be varied as required by the prescribed therapy. For example, the tensile strength of the first layer 405 may be increased for instilling a topical treatment solution. The 25% compressive load deflection of the first layer 405 may be at least 0.35 psi, and the 65% compressive load deflection may be at least 0.43 psi. In some embodiments, the tensile strength of the first layer 405 may be at least 10 psi. The first layer 405 may have a tear strength of at least 2.5 psi. In some embodiments, the first layer 405 may be a foam composed of a polyol (such as a polyester or polyether), an isocyanate (such as toluene diisocyanate), and a polymerization modifier (such as an amine or a tin compound). In a non-limiting example, the first layer 405 may be, for example, a mesh polyurethane foam used in GRANUFOAM™ dressings or VAC VERAFLO™ dressings, both of which are available from Kinetic Concepts, Inc. in San Antonio, Texas.
[0108] The first layer 405 generally has a first planar surface and a second planar surface opposite to the first planar surface. The thickness of the first layer 405 between the first planar surface and the second planar surface can also be varied according to the needs of the prescribed therapy. For example, the thickness of the first layer 405 can be reduced to alleviate stress on other layers and reduce tension on peripheral tissues. The thickness of the first layer 405 may also affect the compliance of the first layer 405. In some embodiments, a thickness in the range of about 5 mm to 10 mm may be suitable.
[0109] The second layer 410 may be a diversion layer, include means for controlling or managing fluid flow, or be substantially composed of therein. In some embodiments, the second layer 410 may include, or be substantially composed of, a liquid-impermeable elastomeric material. For example, the second layer 410 may include, or be substantially composed of, a polymer film. In some embodiments, the second layer 410 may also have a smooth or matte surface texture. A gloss or bright finish better than or equal to grade B3 according to SPI (Plastics Industry Association) standards may be particularly advantageous for certain applications. In some embodiments, variations in surface height may be limited to acceptable tolerances. For example, the surface of the second layer may have a substantially flat surface with height variations limited to 0.2 mm over one centimeter.
[0110] In some embodiments, the second layer 410 may be hydrophobic. In some embodiments, the hydrophobicity of the second layer 410 may vary, but the contact angle with water may be at least 90 degrees. In some embodiments, the contact angle of the second layer 410 with water may not exceed 150 degrees. For example, in some embodiments, the contact angle of the second layer 410 may be in the range of at least 90 degrees to about 120 degrees, or in the range of at least 120 degrees to 150 degrees. Any standard device can be used to measure the water contact angle. While a manual goniometer can be used to visually estimate the contact angle, contact angle measuring instruments typically include an integrated system, which in particular includes a leveling platform, a liquid dropper (e.g., a syringe), a camera, and software designed to calculate the contact angle more accurately and precisely. Non-limiting examples of such integrated systems may include the FTÅ125, FTÅ200, FTÅ2000, and FTÅ4000 systems, all commercially available from First Ten Angstroms, Inc., Portsmouth, VA; and the DTA25, DTA30, and DTA100 systems, all commercially available from Kruss GmbH, Hamburg, Germany. Unless otherwise stated, the water contact angles described herein were measured using deionized and distilled water on a level sample surface with a seat droplet added from a height of no more than 5 cm in air at 20–25°C and 20–50% relative humidity. The contact angles reported herein represent the average of 5 to 9 measurements, discarding both the maximum and minimum measured values. The hydrophobicity of the second layer 410 can be further enhanced with hydrophobic coatings of other materials, such as silicones and fluorocarbons, either liquid-coated or plasma-coated.
[0111] The second layer 410 can also be adapted to be welded to other layers (including the first layer 405). For example, the second layer 410 can be adapted to be welded to polyurethane foam using heat, radio frequency (RF) welding, or other heat-generating methods (such as ultrasonic welding). RF welding is particularly suitable for highly polar materials such as polyurethane, polyamide, polyester, and acrylate. Sacrificial polarity interfaces can be used to facilitate RF welding of less polar membrane materials (such as polyethylene).
[0112] The area density of the second layer 410 can vary depending on the prescribed therapy or application. In some embodiments, an area density of less than 40 grams per square meter may be suitable, and an area density of about 20 to 30 grams per square meter may be particularly advantageous for certain applications.
[0113] In some embodiments, for example, the second layer 410 may comprise, or be substantially composed of, a hydrophobic polymer, such as a polyethylene film. The simple and inert structure of polyethylene can provide a surface that interacts little (if any) with biological tissues and fluids, thus providing a surface that can facilitate free flow of liquids and low adhesion, which can be particularly advantageous for many applications. Other suitable polymer films include polyurethanes, acrylic compounds, polyolefins (e.g., cycloolefin copolymers), polyacetates, polyamides, polyesters, copolyesters, PEBAX block copolymers, thermoplastic elastomers, thermoplastic curing rubbers, polyethers, polyvinyl alcohol, polypropylene, polymethylpentene, polycarbonate, styrene, silicone, fluoropolymers, and acetates. Thicknesses between 20 micrometers and 100 micrometers are suitable for many applications. The film can be transparent, colored, or printed. Suitable polar films laminated onto polyethylene films include polyamides, copolyesters, ionomers, and acrylic compounds. To aid adhesion between the polyethylene and the polar film, a bonding layer, such as ethylene vinyl acetate or modified polyurethane, can be used. Methyl acrylate (EMA) films can also have hydrophobic and weldable properties suitable for certain configurations.
[0114] like Figure 4 As illustrated in the examples, the second layer 410 may have one or more fluid confinement portions 420, which may be uniformly or randomly distributed on the second layer 410. The fluid confinement portions 420 may be bidirectional and pressure-responsive. For example, each fluid confinement portion 420 may generally include or be substantially composed of an elastic channel, which is typically unstrained to significantly reduce fluid flow and may expand or open in response to a pressure gradient. In some embodiments, the fluid confinement portions 420 may include or be substantially composed of perforations in the second layer 410. Perforations may be formed by removing material from the second layer 410. For example, in some embodiments, perforations may be formed by cutting through the second layer 410, which may also deform the edges of the perforations. Where there is no pressure gradient across the perforation, the channel may be small enough to form a seal or fluid confinement, which may significantly reduce or prevent fluid flow. Alternatively or additionally, one or more fluid confinement portions 420 may be elastomeric valves that are normally closed when unstrained to significantly prevent fluid flow and may open in response to a pressure gradient. The opening in the second layer 410 can be a valve suitable for some applications. The opening can also be formed by removing material from the second layer 410, but the amount of material removed and the size of the resulting opening can be at most on the order of a perforation and can avoid deforming the edges.
[0115] For example, some embodiments of the fluid restrictor 420 may include one or more slits, slots, or combinations of slits and slots in the second layer 410, or substantially consist thereof. In some embodiments, the fluid restrictor 420 may include, or consist of, a linear slot having a length of less than 6 mm and a width of less than 3 mm. In some embodiments, the length may be at least 2 mm and the width may be at least 0.4 mm. A length of about 3 mm to about 5 mm and a width of about 0.5 mm to about 2 mm may be particularly suitable for many applications, and a tolerance of about 0.1 mm may also be acceptable. For example, such dimensions and tolerances can be achieved by laser cutting. Such a slot configuration can be used as an imperfect valve, which significantly reduces fluid flow in a normally closed or idle state. For example, such a slot can form a flow restrictor rather than a completely closed or sealed one. The slot can expand or open wider in response to a pressure gradient to allow increased fluid flow.
[0116] exist Figure 4 In the example, dressing 110 may further include an application device, such as adhesive 440. Adhesive 440 may be, for example, a medically acceptable pressure-sensitive adhesive that extends around, partially or entirely around, the periphery of cover 140. In some embodiments, for example, adhesive 440 may be an acrylic adhesive having a coating weight between 25 and 65 grams per square meter (gsm). Figure 4 In the example, the cover includes edges extending beyond the first layer 405 and the second layer 410, and adhesive 440 may be disposed within the edges. In some embodiments, a thicker layer of adhesive or adhesive combination may be applied to improve sealing and reduce leakage. In some embodiments, such an adhesive 440 layer may be continuous or discontinuous. Discontinuity of adhesive 440 may be provided by holes or pores (not shown) in adhesive 440. Holes or pores in adhesive 440 may be formed after the application of adhesive 440 or by patterning adhesive 440 onto a carrier layer, such as the side of cover 140. In some exemplary embodiments, the size of the holes or pores in adhesive 440 may also be determined to enhance the moisture vapor permeation rate of dressing 110.
[0117] like Figure 4As illustrated in the examples, in some embodiments, dressing 110 may include a release liner 445 to protect adhesive 440 prior to use. Release liner 445 may also provide stiffness, thereby facilitating the deployment of dressing 110. Release liner 445 may be, for example, cast paper, film, or polyethylene. Furthermore, in some embodiments, release liner 445 may be a polyester material, such as polyethylene terephthalate (PET) or a similar polar semicrystalline polymer. The use of a polar semicrystalline polymer in release liner 445 can substantially prevent wrinkling or other deformation of dressing 110. For example, the polar semicrystalline polymer may be highly oriented and resistant to softening, swelling, or other deformation that may occur upon contact with components of dressing 110 or upon exposure to temperature or environmental changes or sterilization. Additionally, a release agent may be disposed on the sides of release liner 445 configured to contact the second layer 410. For example, the release agent may be a silicone coating and may have a release factor suitable for facilitating manual removal of the release liner 445 without damaging or deforming the dressing 110. In some embodiments, the release agent may be a fluorocarbon or a fluorosilicone. In other embodiments, the release liner 445 may be uncoated or otherwise not coated with a release agent.
[0118] Figure 4 An example of the fluid conduction element 450 and the dressing interface 455 is also shown. Figure 4 As shown in the example, the fluid conductor 450 can be a flexible tube, one end of which can be fluidly connected to the dressing interface 455. The dressing interface 455 can be an elbow connector, such as... Figure 4 As shown in the example, the elbow connector can be placed on the hole 460 in the cover 140 to provide a fluid path between the fluid conductor 450 and the tissue interface 135.
[0119] Figure 5 This is a schematic diagram of an example of the second layer 410, illustrating additional details that can be associated with some embodiments. For example... Figure 5 As shown in the example, the fluid restriction section 420 can each consist essentially of one or more linear slots having a length of about 3 mm. Figure 5 An example of a uniformly distributed pattern in the fluid restriction section 420 is also shown. Figure 5 In this configuration, the fluid restricting portions 420 are substantially coaxial with the second layer 410 and are distributed on the second layer 410 in a grid of parallel rows and columns, wherein these slots are also parallel to each other. In some embodiments, the centers of these rows may be spaced approximately 3 mm apart, and the centers of the fluid restricting portions 420 within each row may be spaced approximately 3 mm apart, such as... Figure 5 As shown in the example, the fluid restriction sections 420 in adjacent rows can be aligned or offset. For example, as... Figure 5As shown, adjacent rows may be offset such that the fluid restrictors 420 are aligned in alternating rows and spaced approximately 6 mm apart. In some embodiments, the spacing of the fluid restrictors 420 may be varied to increase the density of the fluid restrictors 420 according to treatment needs.
[0120] In some embodiments, one or more components of dressing 110 may be additionally treated with an antimicrobial agent. For example, the first layer 405 may be a foam, mesh, or nonwoven fabric coated with an antimicrobial agent. In some embodiments, the first layer 405 may include an antimicrobial element, such as fibers coated with an antimicrobial agent. Additionally or alternatively, some embodiments of the second layer 410 may be a polymer coated or infused with an antimicrobial agent. In other examples, the fluid conduction element 450 may be additionally or alternatively treated with one or more antimicrobial agents. Suitable antimicrobial agents may include, for example, metallic silver, PHMB, iodine or complexes and mixtures thereof (such as povidone-iodine), copper compounds, chlorhexidine, or some combination of these materials.
[0121] Alternatively or concurrently, one or more of the components may be coated with a mixture that may contain citric acid and collagen, which can reduce biofilm and infection. For example, the first layer 405 may be a foam coated with such a mixture.
[0122] The various components of dressing 110 can be bonded to each other by solvent-based or non-solvent-based adhesives, or by means of, for example, thermal welding, or otherwise, without adversely affecting fluid management.
[0123] The cover 140, the first layer 405, and the second layer 410, or multiple different combinations thereof, can be assembled prior to application or in the field. For example, in some embodiments, the cover 140 may be laminated onto the first layer 405, and the second layer 410 may be laminated onto the first layer 405, opposite to the cover 140. The second layer 410 may provide a smooth surface opposite to the first layer 405. In some embodiments, one or more layers of the tissue interface 135 may be co-extended. For example, the second layer 410 may be cut flush with the edge of the first layer 405, thereby exposing the edge of the first layer 405, such as... Figure 4 As illustrated in the embodiments. In other embodiments, the second layer 410 may be superimposed on the edge of the first layer 405. In some embodiments, the dressing 110 may be provided as a single composite dressing. For example, the second layer 410 may be attached to the cover 140 to enclose the first layer 405, wherein the second layer 410 is configured to face the tissue site.
[0124] In use, the release liner 445 (if included) can be removed to expose the second layer 410, which can be placed within, above, over, or otherwise close to the tissue site, particularly the surface tissue site and adjacent epidermis. The second layer 410 can be positioned between the first layer 405 and the tissue site and adjacent epidermis, which can significantly reduce or eliminate adverse interactions with the first layer 405. For example, the second layer 410 can be placed over the surface wound (including the wound edges) and undamaged epidermis to prevent direct contact with the first layer 405. Treating a surface wound, or placing the dressing 110 on a surface wound, includes placing the dressing 110 close to the body surface or extending over at least a portion of the body surface. Treating a surface wound does not include placing the dressing 110 entirely within the body or entirely below the body surface, such as placing the dressing inside the abdominal cavity. The cover 140 can seal around the first layer 405 and the second layer 410 to the surface to which it is attached, such as the epidermis surrounding the tissue site.
[0125] The geometry and dimensions of the tissue interface 135, the cap 140, or both can be modified to suit a specific application or anatomical structure. For example, the geometry or dimensions of the tissue interface 135 and the cap 140 can be adapted to provide an effective and reliable seal relative to challenging anatomical surfaces at or around the tissue site, such as the elbow or heel. Alternatively or additionally, dimensions can be modified to increase the surface area of the second layer 410, thereby enhancing the movement and proliferation of epithelial cells at the tissue site and reducing the likelihood of inward granulation tissue growth.
[0126] Therefore, in Figure 4 In the example, dressing 110 can provide a sealed therapeutic environment that is essentially isolated from the external environment near the tissue site, and negative pressure source 105 can reduce the pressure in the sealed therapeutic environment.
[0127] The fluid dynamics of using a negative pressure source to reduce pressure in another component or location (such as within a sealed therapeutic environment) can be mathematically complex. However, the basic principles of fluid dynamics applicable to negative pressure therapy and infusion are generally well known to those skilled in the art, and the process of reducing pressure can be illustratively described herein as, for example, “delivering,” “distributing,” or “generating” negative pressure.
[0128] Generally, exudates and other fluids flow along the fluid path toward lower pressure. Therefore, the term "downstream" typically refers to a location relatively closer to a negative pressure source or further away from a positive pressure source within the fluid path. Conversely, the term "upstream" refers to a location relatively further away from a negative pressure source or closer to a positive pressure source. Similarly, it may be appropriate to describe certain features in this frame of reference according to the fluid's "inlet" or "outlet." This orientation is generally assumed to be for describing the different features and components described herein. However, in some applications, the fluid path can be reversed (e.g., by replacing the negative pressure source with a positive pressure source), and this descriptive convention should not be construed as restrictive.
[0129] In some embodiments, negative pressure in the sealed environment can compress the first layer 405 into the second layer 410, which can cause the surface of the second layer 410 to deform to provide an uneven, rough, or jagged profile, potentially inducing macro- and micro-strain in the tissue site. The negative pressure applied through the tissue interface 135 can also create a negative pressure differential across the fluid confinement portion 420 in the second layer 410, which can cause the fluid confinement portion 420 to open, allowing exudates and other fluids to move through the fluid confinement portion 420 into the first layer 405 and the container 115. For example, in some embodiments where the fluid confinement portion 420 may include perforations through the second layer 410, the pressure gradient across these perforations can cause strain in the adjacent material of the second layer 410 and increase the size of the perforations to allow fluid to move through them, similar to the operation of a duckbill valve.
[0130] In some embodiments, controller 120 may receive and process data from one or more sensors, such as first sensor 125. Controller 120 may also control the operation of one or more components of the therapy system 100 to manage pressure delivered to tissue interface 135. In some embodiments, controller 120 may include input for receiving a desired target pressure and may be programmed to process data relating to the setting and input of the target pressure to be applied to tissue interface 135. In some exemplary embodiments, the target pressure may be a fixed pressure value set by an operator to achieve the desired target negative pressure at the tissue site and then provided as input to controller 120. The target pressure may vary between tissue sites based on the type of tissue forming the tissue site, the type of injury or wound (if any), the patient's medical condition, and the attending physician's preference. After selecting the desired target pressure, controller 120 may operate negative pressure source 105 in one or more control modes based on the target pressure and may receive feedback from one or more sensors to maintain the target pressure at tissue interface 135.
[0131] In some embodiments, the first layer 405 may be hydrophobic to minimize liquid retention or storage in the dressing 110. In other embodiments, the first layer 405 may be hydrophilic to retain exudate or infusion solutions. In examples where the first layer 405 may be hydrophilic, the first layer 405 may also wick fluid from the tissue site while continuing to distribute negative pressure to the tissue site. For example, the wicking properties of the first layer 405 may draw fluid from the tissue site via capillary flow or other wicking mechanisms. Examples of hydrophilic materials suitable for the first layer 405 are polyvinyl alcohol open-cell foams, such as the VAC WHITEFOAM™ dressing from KCI, San Antonio, Texas. Other hydrophilic foams may include hydrophilic foams made of polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.
[0132] If the negative pressure source 105 is removed or turned off, the pressure difference on the fluid confinement section 420 can dissipate, thereby allowing the fluid confinement section 420 to return to a strain-free or idle state and preventing or reducing the return rate of exudate or other fluids through the second layer 410 to the tissue site.
[0133] In some applications, a filler may also be disposed between the tissue site and the second layer 410. For example, if the tissue site is a surface wound, a wound filler may be applied inside the wound periphery, and the second layer 410 may be disposed around the wound and above the wound filler. In some embodiments, the filler may be a manifold, such as open-cell foam. In some embodiments, the filler may comprise or consist substantially of the same material as the first layer 405.
[0134] Alternatively, an infusion solution or other fluid may be distributed into the dressing 110, which may increase the pressure in the tissue interface 135. The increased pressure in the tissue interface 135 may create a positive pressure differential on the fluid confinement portion 420 in the second layer 410, which may cause the fluid confinement portion 420 to open or expand from its idle state to allow the infusion solution or other fluid to be distributed to the tissue site.
[0135] Figure 6 yes Figure 1 Another example of an assembled view of the dressing 110 shows additional details that may be associated with some embodiments where the tissue interface 135 therein may include additional layers. Figure 6 In the example, the tissue interface 135 includes a third layer 605 in addition to the first layer 405 and the second layer 410. In some embodiments, the third layer 605 may be adjacent to the second layer 410 and opposite to the first layer 405. In some embodiments, the third layer 605 may also be bonded to the second layer 410.
[0136] The third layer 605 may include or substantially consist of a fixing layer having a tacky surface and formed of a soft polymer suitable for providing a fluid seal with tissue sites. In some examples, the third layer may be a polymeric gel having a coating weight of about 250 gsm and may have a substantially flat surface. For example, the third layer 605 may include: silicone gel, soft silicone, hydrocolloid, hydrogel, polyurethane gel, polyolefin gel, hydrogenated styrene copolymer gel, foam gel, closed-cell foam (such as polyurethane and polyolefin coated with an adhesive), or acrylic compound. In some embodiments, the third layer 605 may have a thickness between about 200 micrometers (μm) and about 1000 micrometers (μm). In some embodiments, the third layer 605 may have a hardness between about 5 Shore 00 and about 80 Shore 00. Additionally, the third layer 605 may be composed of a hydrophobic or hydrophilic material.
[0137] In some embodiments, the third layer 605 may be a hydrophobic coating material. For example, the third layer 605 may be formed by coating a spacer material (such as a woven, nonwoven, molded, or extruded mesh) with a hydrophobic material. For example, the hydrophobic material used for coating may be soft silicone.
[0138] The third layer 605 may have a periphery 610 surrounding or surrounding the inner portion 615 and may have an aperture 620 disposed through the periphery 610 and the inner portion 615. In some examples, the inner portion 615 may correspond to the surface area of the first layer 405. The third layer 605 may also have corners 625 and edges 630. These corners 625 and edges 630 may be part of the periphery 610. The third layer 605 may have an inner boundary 635 surrounding the inner portion 615, which is disposed between the inner portion 615 and the periphery 610. The inner boundary 635 may be substantially without the aperture 620, as... Figure 6 As shown in the examples. In some examples, such as Figure 6 As shown, the internal portion 615 can be symmetrically and centrally arranged in the third layer 605.
[0139] The aperture 620 can be formed by cutting, or by applying localized RF or ultrasonic energy, or by other suitable techniques for forming openings. The aperture 620 can have a uniform distribution pattern or can be randomly distributed on the third layer 605. The apertures 620 in the third layer 605 can have a variety of shapes, including, for example, circular, square, star-shaped, oval, polygonal, slit, complex curve, straight line, triangular, or some combination of such shapes.
[0140] Each hole 620 may have uniform or similar geometric characteristics. For example, in some embodiments, each hole 620 may be a circular hole having substantially the same diameter. In some embodiments, the diameter of each hole 620 may be between about 1 mm and about 50 mm. In other embodiments, the diameter of each hole 620 may be between about 1 mm and about 20 mm. In some embodiments, the diameter of each hole 620 may be between about 2 mm and about 5 mm.
[0141] In other embodiments, the geometry of the aperture 620 can be varied. For example, the diameter of the aperture 620 can vary depending on its position within the third layer 605, such as... Figure 6 As shown. In some embodiments, the diameter of the hole 620 located in the periphery 610 of the third layer 605 may be larger than the diameter of the hole 620 located in the inner portion 615 of the third layer 605. For example, in some embodiments, the diameter of the hole 620 arranged in the periphery 610 may be between about 9.8 mm and about 10.2 mm. In some embodiments, the diameter of the hole 620 arranged in the corner 625 may be between about 7.75 mm and about 8.75 mm. In some embodiments, the diameter of the hole 620 arranged in the inner portion 615 may be between about 2 mm and about 5 mm.
[0142] At least one hole 620 in the periphery 610 of the third layer 605 can be positioned at an edge 630 of the periphery 610 and can have an internal cutout that opens or exposes at the edge 630, the internal cutout being in fluid communication with these edges 630 in a lateral direction. This lateral direction can refer to a direction toward the edge 630 and coplanar with the third layer 605. Figure 6 As shown in the example, holes 620 in the periphery 610 can be positioned near or at edges 630 and are in fluid communication with these edges 630 in the lateral direction. Holes 620 positioned near or at edges 630 can be spaced substantially equidistantly around the periphery 610, such as... Figure 6 As shown in the example. Alternatively, the spacing of the holes 620 near or at edge 630 can be irregular.
[0143] like Figure 6 As illustrated in the examples, in some embodiments, the release liner 445 may be attached to or positioned adjacent to the third layer 605 to protect the adhesive 440 prior to use. In some embodiments, the release liner 445 may have a surface texture that can be printed onto an adjacent layer, such as the third layer 605. Furthermore, a release agent may be disposed on the side of the release liner 445 configured to contact the third layer 605.
[0144] Figure 7This is a schematic diagram of an exemplary configuration of hole 620, illustrating additional details that may be associated with some embodiments of the third layer 605. In some embodiments, Figure 7 The hole 620 shown can be associated only with the internal portion 615. Figure 7 In the example, hole 620 is generally circular and has a diameter of about 2 millimeters. Figure 7 An example of a uniformly distributed pattern of holes 620 in the internal portion 615 is also shown. Figure 7 In the diagram, the holes 620 are distributed in a grid of parallel rows and columns. Within each row and column, the holes 620 can be equidistant from each other, as shown below. Figure 7 The example shown is as follows. Figure 7 An exemplary configuration is shown that can be particularly well-suited for many applications, in which the holes 620 can be spaced approximately 6 mm apart and offset 3 mm along each row and column.
[0145] Figure 8 yes Figure 7 Hole 620 superimposed on Figure 5 The schematic diagram on the fluid restriction section 420 illustrates additional details that can be associated with some exemplary embodiments of the tissue interface 135. For example, as Figure 8 As shown, in some embodiments, the fluid restrictor 420 may be aligned, overlapped, aligned, or otherwise fluidly connected to the orifice 620. In some embodiments, one or more fluid restrictors of the fluid restrictor 420 may be aligned with the orifice 620 in the internal portion 615 only, or only partially aligned with the orifice 620. Figure 8 In the example, the fluid restrictors 420 are generally configured such that each fluid restrictor 420 is aligned with only one hole 620. In other examples, one or more fluid restrictors 420 may be aligned with more than one hole 620. For example, any one or more fluid restrictors 420 may be a perforation or window extending across two or more holes 620. Alternatively or concurrently, one or more fluid restrictors 420 may not be aligned with any hole 620.
[0146] like Figure 8As illustrated in the examples, the size of the orifice 620 can be determined to expose a portion of the second layer 410, the fluid confinement portion 420, or both, through the third layer 605. In some embodiments, the size of one or more orifices 435 can be determined to expose more than one fluid confinement portion 420. For example, some or all of the orifices 435 can be determined to expose two or three fluid confinement portions 420. In some embodiments, the length of each fluid confinement portion 420 can be substantially equal to the diameter of each orifice 620. More generally, the average size of the fluid confinement portions 420 can be substantially similar to the average size of the orifices 620. For example, in some embodiments, the orifice 620 can be elliptical, and the length of each fluid confinement portion 420 can be substantially equal to its major or minor axis. However, in some embodiments, the size of the fluid confinement portion 420 can be larger than the size of the orifice 620, and the size of the orifice 620 can limit the effective size of the fluid confinement portion 420 exposed to the lower surface of the dressing 110.
[0147] Figure 6 In the example, the various components of dressing 110 can be bonded to each other by solvent-based or non-solvent-based adhesives, or by means of, for example, thermal welding, or otherwise, without adversely affecting fluid management. Additionally, the second layer 410 or the first layer 405 can be joined to the boundary 635 of the third layer 605 in any suitable manner, such as by welding or adhesive.
[0148] The cover 140, first layer 405, second layer 410, third layer 605, or a variety of different combinations thereof, can be assembled prior to application or in the field. For example, in some embodiments, the cover 140 may be laminated onto the first layer 405, and the second layer 410 may be laminated onto the first layer 405, opposite to the cover 140. In some embodiments, the third layer 605 may also be coupled to the second layer 410, opposite to the first layer 405. In some embodiments, one or more layers of the tissue interface 135 may be co-extended. For example, the second layer 410, the third layer 605, or both may be cut flush with the edge of the first layer 405, thereby exposing the edge of the first layer 405, such as... Figure 6 The embodiments illustrated herein. In other embodiments, the second layer 410, the third layer 605, or both may be superimposed on the edge of the first layer 405. In some embodiments, the dressing 110 may be provided as a single composite dressing. For example, the third layer 605 may be attached to the cover 140 to enclose the first layer 405 and the second layer 410, wherein the third layer 605 is configured to face the tissue site. Alternatively or additionally, the second layer 410, the third layer 605, or both may be disposed on two sides of the first layer 405 and bonded together to enclose the first layer 405.
[0149] exist Figure 6In the example, removing the release liner 445 can also expose the adhesive 440, and the cover 140 can be attached to an attachment surface, such as the epidermis surrounding a tissue site, around the first layer 405 and the second layer 410. For example, the adhesive 440 can be in fluid communication with the attachment surface through holes 620 in at least the periphery 610 of the third layer 605. The adhesive 440 can also be in fluid communication with the edge 630 through holes 620 exposed at the edge 630.
[0150] Once the dressing 110 is in the desired position, the adhesive 440 can be pressed through the hole 620 to bond the dressing 110 to the attachment surface. The hole 620 at the edge 630 allows the adhesive 440 to flow around the edge 630 to enhance the adhesion between the edge 630 and the attachment surface.
[0151] In some embodiments, the size of the holes or openings in the third layer 605 can be determined to control the amount of adhesive 440 in fluid communication with the holes 620. For a given geometry of the corner 625, the relative size of the holes 620 can be configured to maximize the surface area of the adhesive 440 exposed at the corner 625 and in fluid communication through the holes 620 at the corner. For example, as Figure 6 As shown, edges 630 may intersect substantially right-angled or at approximately 90 degrees to define corner 625. In some embodiments, corner 625 may have a radius of approximately 10 mm. Additionally, in some embodiments, three of the holes 620 having a diameter between approximately 7.75 mm and approximately 8.75 mm may be positioned in a triangular configuration at corner 625 to maximize the exposed surface area of adhesive 440. In other embodiments, the size and number of holes 620 in corner 625 may be adjusted, if necessary, depending on the selected geometry of corner 625 to maximize the exposed surface area of adhesive 440. Furthermore, the holes 620 at corner 625 may be completely contained within third layer 605, significantly preventing lateral fluid communication outside corner 625. The holes 620 at corner 625, completely contained within third layer 605, significantly prevent fluid communication of adhesive 440 outside corner 625 and can provide improved manipulation of the dressing during application of dressing 110 to the tissue site. In addition, the essentially adhesive-free exterior of corner 625 can increase the flexibility of corner 625 to improve comfort.
[0152] In some embodiments, the adhesive strength of adhesive 440 can vary at different locations on dressing 110. For example, adhesive 440 can have lower adhesive strength in locations adjacent to the third layer 605 (where the orifice 620 is relatively large) and higher adhesive strength in locations where the orifice 620 is smaller. Combining adhesive 440 with lower adhesive strength with larger orifices 620 can provide an adhesion comparable to that of adhesive 440 with higher adhesive strength at locations with smaller orifices 620.
[0153] The geometry and dimensions of the tissue interface 135, the cap 140, or both can be modified to suit a specific application or anatomical structure. For example, the geometry or dimensions of the tissue interface 135 and the cap 140 can be adapted to provide an effective and reliable seal relative to challenging anatomical surfaces at or around the tissue site (e.g., the elbow or heel). Alternatively or additionally, dimensions can be modified to increase the surface area of the third layer 605, thereby enhancing the movement and proliferation of epithelial cells at the tissue site and reducing the likelihood of inward granulation tissue growth.
[0154] Therefore, in Figure 6 In this example, dressing 110 can provide a sealed therapeutic environment that is substantially isolated from the external environment close to the tissue site, and negative pressure source 105 can reduce pressure within the sealed therapeutic environment. A third layer 605 can provide an effective and reliable seal relative to challenging anatomical surfaces at or around the tissue site, such as the elbow or heel. Additionally, dressing 110 can allow for reapplication or repositioning to, for example, correct air leaks caused by wrinkles and other discontinuities in dressing 110. In some embodiments, the ability to correct leaks can increase the efficacy of the therapy and reduce power consumption.
[0155] If not already configured, the dressing port 455 can be positioned above the hole 460 and attached to the cover 140. The fluid conductor 450 can be fluidly connected to the dressing port 455 and the negative pressure source 105.
[0156] The negative pressure applied through tissue interface 135 can create a negative pressure differential on the fluid confinement portion 420 in the second layer 410, which can cause the fluid confinement portion 420 to open or expand. For example, in some embodiments where the fluid confinement portion 420 may include a substantially closed window through the second layer 410, the pressure gradient across the window can cause strain in the adjacent material of the second layer 410 and increase the size of the window to allow liquid movement through it, similar to the operation of a duckbill valve. Opening the fluid confinement portion 420 allows exudates and other fluids to move through the fluid confinement portion 420 into the first layer 405 and container 115. Pressure changes can also cause the first layer 405 to expand and contract, and the inner boundary 635 can protect the epidermis from irritation. The second layer 410 and the third layer 605 can also significantly reduce or prevent tissue exposure to the first layer 405, which can inhibit tissue growth into the first layer 405.
[0157] If the negative pressure source 105 is removed or turned off, the pressure difference on the fluid restriction section 420 can dissipate, thereby allowing the fluid restriction section 420 to close and preventing exudate or other fluids from passing through the second layer 410 back to the tissue site.
[0158] In some applications, a filler may also be disposed between the tissue site and the third layer 605. For example, if the tissue site is a surface wound, a wound filler may be applied inside the wound periphery, and the third layer 605 may be disposed around the wound and above the wound filler. In some embodiments, the filler may be a manifold, such as open-cell foam. In some embodiments, the filler may comprise or consist substantially of the same material as the first layer 405.
[0159] Alternatively, an infusion solution or other fluid can be distributed into the dressing 110, which can increase the pressure in the tissue interface 135. The increased pressure in the tissue interface 135 can create a positive pressure differential on the fluid confinement section 420 in the second layer 410, which can open the fluid confinement section 420 to allow the infusion solution or other fluid to be distributed to the tissue site.
[0160] Figure 9 This is a top view of another example of the third layer 605, showing additional details that can be associated with some embodiments. (See image.) Figure 9 As shown in the example, instead of or attached to the orifice 620 in the internal portion 615, the third layer 605 may have one or more elastomeric valves 905. Attached to or replacing the second layer 410, the third layer 605 may include valves 905. In some embodiments where the third layer 605 includes one or more valves 905, the second layer 410 may be omitted. For example, in some embodiments, the tissue interface 135 may be substantially composed of the first layer 405 and... Figure 9It consists of a third layer 605 having a valve 905 arranged in the internal portion 615.
[0161] Figure 10 and Figure 11 Other exemplary configurations of valve 905 are shown, wherein each valve 905 generally includes a combination of intersecting slits or cross slits.
[0162] Figure 12 This is a schematic cross-sectional view of an example dressing 110, illustrating additional details that can be associated with some embodiments. Figure 12 In the example, the organization interface 135 includes a first layer 405, a second layer 410, and a third layer 605 assembled in a stacked configuration, wherein the second layer 410 is disposed between the first layer 405 and the third layer 605. Figure 12 The cover 140 is disposed on the first layer 405. The cover 140 significantly encloses the edge of the tissue interface 135.
[0163] like Figure 12 As illustrated in the exemplary configuration, perforations 415 may extend through the first layer 405. One or more perforations 415 may be through-holes extending through the first layer 405 from a first surface adjacent to the cover 140 to a second surface adjacent to the second layer 410. In other embodiments, one or more perforations 415 may be blind holes that do not completely penetrate the first layer 405. For example, one or more perforations 415 may extend from the first surface into the first layer 405, and their depth may be less than the thickness of the first layer 405.
[0164] Perforation 415 may form a wall 1205 in the first layer 405. In some embodiments, wall 1205 may be cylindrical. In yet other embodiments, perforation 415 may be conical and may have conical, pyramidal, or other irregular geometries.
[0165] Figure 13 This is a cross-sectional schematic diagram of another exemplary configuration of the organization interface 135. Figure 13 In some examples, one or more fluid confinements in fluid confinement 420 may be configured to expand under a pressure gradient to contact at least a portion of wall 1205. For example, one or more fluid confinements in fluid confinement 420 may include or be composed of intersecting slits, which may form flaps that can contact at least a portion of wall 1205. These flaps may prevent or reduce tissue growth inward into the first layer 405. In some examples, granulation tissue may also cause fluid confinement 420 to expand. In some embodiments having a third layer 605, one or more fluid confinements in fluid confinement 420 may be aligned with one or more holes in orifice 620.
[0166] Figure 14 This is a plan view of an example of the first layer 405, showing additional details that can be associated with some embodiments. For example, some embodiments of the perforation 415 may have a circular cross-section, such as... Figure 14 As shown. In some embodiments, the average diameter of the perforation 415 can be from about 2 mm to about 10 mm, and the centers of the perforations 415 can be spaced between about 2 mm and about 10 mm apart. The perforations 415 can be aligned with some or all of the fluid restriction portion 420 and the holes 620 or not aligned at all.
[0167] In some embodiments, the first layer 405 may have a first orientation line 1405 and a second orientation line 1410 perpendicular to the first orientation line 1405. The first orientation line 1405 and the second orientation line 1410 may be lines of symmetry passing through the first layer 405. Figure 14 In the example, the first layer 405 has an overall rectangular shape and has a longitudinal edge 1415 and a transverse edge 1420. In some embodiments, the first orientation line 1405 may be parallel to the longitudinal edge 1415.
[0168] In some embodiments, the longitudinal edge 1415 and the transverse edge 1420 of the first layer 405 may not be straight edges. For example, one or more perforations in the perforations 415 may be superimposed on the longitudinal edge 1415 or the transverse edge 1420, resulting in a non-linear profile at the edges, which can reduce disruption to keratinocyte migration and enhance epithelial reformation through negative pressure therapy.
[0169] The first layer 405 can also have a variety of other suitable shapes. For example, the first layer 405 can have a rhomboid, square, or circular shape. In some embodiments, the shape of the first layer 405 can be selected to adapt to the shape or type of the tissue site. For example, the first layer 405 can have an oval or circular shape to adapt to oval or circular tissue sites.
[0170] In some embodiments, the perforations 415 may be aligned in parallel rows to form an array, such as Figure 14 As illustrated in the examples. In some embodiments, the width of the wall 1205 between the perimeters of two or more perforations 415 in a row may be approximately 5 millimeters. The center of each perforation 415 in an adjacent row may be characterized as offset along a first orientation line 1405.
[0171] Figure 15 and Figure 16 This is a plan view of another example of the first layer 405, showing additional details that can be associated with some embodiments. For example... Figure 15 and Figure 16 As shown, some embodiments of the perforation 415 may have a polygonal cross-section. Figure 15An example is shown where each perforation has a hexagonal cross-section. Figure 16 An example is shown where each perforation has a triangular cross-section. In some embodiments, perforation 415 may have an effective diameter between approximately 2 mm and approximately 10 mm. The effective diameter of the non-circular region is the diameter of a circular region having the same surface area as the non-circular region.
[0172] Figure 17 This is a plan view of another example of the first floor 405, showing additional details that can be associated with some embodiments. Figure 17 In the example, each perforation 415 has an elliptical cross-section.
[0173] Figure 18 This is a top view of another example of the first layer 405, showing additional details that can be associated with some embodiments. For example, Figure 18 An embodiment of a first layer 405 is shown, which has an interior 1805 and a boundary 1810 extending around the interior 1805. Figure 18 The perforation 415 is only arranged in the interior 1805; the boundary 1810 is adjacent to the interior 1805 and does not have a perforation. The outline of the perforation 415 can be circular (e.g., ...). Figure 18 The inner 1805 (as shown in the examples) or it may have other contours (as shown in other examples). The dimensions of the inner 1805 and the boundary 1810 can also be varied. For example, the width W1 of the boundary 1810 can be from about 1 cm to about 5 cm. In some examples, the shape and size of the inner 1805 can be determined to be similar to the second layer 410.
[0174] Figure 19 This is a top view of another example of the first layer 405, showing additional details that can be associated with some embodiments. Figure 19 In the example, in addition to the interior 1805, at least some perforations 415 may also be arranged in the boundary 1810. The perforations 415 in the boundary 1810 may have a width W2, and the perforations 415 in the interior 1805 may have a second width W3. The width W2 is generally smaller than the width W3. For example, the width W3 may be at least twice the width W2. In some examples, the width W2 may be from about 1 mm to about 8 mm, and the width W3 may be between about 2 mm and about 10 mm.
[0175] Figure 20 This is a top view of another example of the first layer 405, showing additional details that can be associated with some embodiments. Figure 20In some examples, the first layer 405 may have a variable density. For example, the first layer 405 may include a region 2005 having a first density and a region 2010 having a second density. In some embodiments, the second density is greater than the first density. In some examples, regions 2005 and 2010 may include different materials with different densities or are substantially composed of them. In other examples, regions 2005 and 2010 may include the same or similar materials or are substantially composed of them, and these materials may be processed to change their density. For example, region 2005 may include uncompressed open-cell foam or is substantially composed of it, and region 2010 may include compressed open-cell foam or is substantially composed of it. In some embodiments, the second density may be between about 3 and about 5 times the first density.
[0176] Compressed foam is foam that is mechanically or chemically compressed to increase its density under ambient pressure. A characteristic of compressed foam may be a hardness coefficient, defined as the ratio of the density of the foam in its compressed state to the density of the same foam in its uncompressed state. In some examples, region 2010 may include foam with a hardness coefficient of approximately 5 or be substantially composed of it. Increasing the hardness coefficient of the foam can increase its stiffness in the direction parallel to its thickness. For example, increasing the hardness coefficient of region 2010 can increase the stiffness of the first layer 405 in the direction parallel to its thickness.
[0177] Compressed foam can also be called "felt foam." Felt foam undergoes a thermoforming process to permanently compress the foam, increasing its density. Felt foam can also be compared to other felted or compressed foams by comparing its stiffness coefficient to that of other compressed or uncompressed foams. Generally, compressed or felted foams can have a stiffness coefficient greater than 1.
[0178] In general, when compressed foam is subjected to negative pressure, it exhibits less deformation than similar uncompressed foam. In some embodiments, region 2005 may have greater compressibility than region 2010. For example, if region 2005 is formed of uncompressed foam and region 2010 is formed of compressed foam, then region 2010 may deform less than region 2005. The reduction in deformation may be caused by the increased stiffness reflected in the hardness coefficient. If subjected to negative compressive stress, the flatness of region 2010 formed of compressed foam may be less than that of region 2005 formed of uncompressed foam. The degree of compression may be inversely proportional to the degree of felting. For example, the compression of a 10 mm thick foam piece with a hardness coefficient of 2 will be half that of a 10 mm thick foam piece with a hardness coefficient of 1. In some embodiments, the first layer 405 may have a thickness of about 8 mm, and region 2010 may compress less under negative pressure than region 2005. For example, region 2010 can be reduced to a thickness of about 6 mm, and region 2005 can be reduced to a thickness of about 3 mm.
[0179] In some embodiments, Figure 20 The first layer 405 can be formed from a foam block. An uncompressed foam block with six sides can be provided. Multiple channels can be formed in the first surface of the block. For example, the first surface can be cut to form channels. Cutting can include laser cutting, computer numerical control (“CNC”) hot wire cutting, and pressing the foam block through holes in a plate configured to shear off material, then splitting the foam. Cutting can also include egg-crating, for example, cutting the foam using a specially designed band saw operable to cut the foam simultaneously at variable depths. In some embodiments, channels can also be formed in a second surface of the block. For example, the second surface can be located on the side of the block opposite to the first surface. The channels on the second surface can be aligned with the channels on the first surface. The channels can be parallel, and each channel can extend along the length or width of the block and its width or length is substantially equal to the width of region 2005. In some embodiments, the channels have a square or rectangular shape. The formation of the channels creates a series of parallel walls extending from the first surface of the foam block. Viewed from a side perpendicular to the first surface, the first surface can have an undulating morphology similar to a square wave shape. In other embodiments, channels with circular, triangular, or amorphous shapes can be formed to generate sine waves, sawtooth (triangular) waves, or amorphous wave profiles, respectively.
[0180] After the channels are formed, the block can be compressed or felted. For example, a first and a second surface can be positioned between two plates designed to heat the block. After heating to an optimal temperature for a particular foam, the plates can compress the foam. The plates hold the foam in a compressed state until it cools to ambient temperature, thus maintaining the thickness of the compressed state. In some embodiments, the block can be felted or compressed until it has a substantially uniform thickness, thereby forming a first layer 405 with a substantially uniform thickness. Feltting the foam block to have a substantially uniform thickness compresses the walls, making the wall density greater than that of adjacent channels. After felting, the channel-forming region 2005 and the compressed wall-forming region 2010 are formed. Relative to region 2005, at region 2010, the felting process produces regions 2005 and 2010 with different densities because more material is compressed into the new volume created by the felting process. In other embodiments, the thickness of the first layer 405 can vary slightly between regions 2005 and 2010.
[0181] like Figure 20 As shown in the examples, regions 2005 and 2010 can have rectangular outlines. In other examples, region 2005, region 2010, or at least some of them, can have other geometric outlines (such as circles or hexagons). Regions 2005 and 2010 can also be distributed in a rectangular pattern, such as... Figure 20 As shown in the examples. In some examples, such as Figure 20 Patterns can be represented as rows or parallel stripes. In other examples, suitable patterns can be represented as arrays, grids, or intersecting shadows. Concentric rings may also be suitable for some examples.
[0182] Figure 21 yes Figure 1 Another example of the dressing 110 is shown in an assembled view, illustrating additional details that can be associated with some embodiments. Figure 21 In the example, tissue interface 135 includes a retaining layer 2105 disposed between cover 140 and first layer 405. In some embodiments, retaining layer 2105 may include or be substantially composed of a manifold (such as open-cell foam), which may be arranged adjacent to perforation 415. For example, retaining layer 2105 may include or be substantially composed of a mesh foam having a relatively large pore size. Foam having between 10 and 80 pores per inch may be suitable for some examples. Retaining layer 2105 may be flexible, semi-rigid, or rigid. In some embodiments, retaining layer 2105 may be more flexible or compressible than first layer 405. In some examples, the density of retaining layer 2105 may be less than that of first layer 405. In some embodiments, retaining layer 2105 may be thinner than first layer 405.
[0183] In some embodiments, the first layer 405 and the retaining layer 2105 may be integrated into a single component or a single layer, and may be inseparable. For example, in some embodiments, the retaining layer 2105 may be laminated onto the first layer 405.
[0184] Figure 22 This is a flowchart illustrating details that can be associated with exemplary methods for operating the therapy system 100 to provide negative pressure therapy and infusion therapy to the tissue interface 135. In some embodiments, the controller 120 may receive and process data, such as data relating to the infusion solution provided to the tissue interface 135. Such data may include the type of infusion solution specified by a clinician, the volume of fluid or solution to be infused into the tissue site (“fill volume”), and a specified amount of time (“retention time”) for which the solution remains at the tissue site before negative pressure is applied. The fill volume may be, for example, between 10 and 500 mL, and the residence time may be between 1 second and 30 minutes. The controller 120 may also control the operation of one or more components of the therapy system 100 to infuse the solution, as indicated at 2205. For example, the controller 120 may manage the distribution of fluid from the solution source 145 to the tissue interface 135. In some embodiments, fluid can be dripped into the tissue site by applying negative pressure from negative pressure source 105 to reduce pressure at the tissue site, thereby drawing the solution into tissue interface 135, as indicated at 2210. In some embodiments, solution can be dripped into the tissue site by applying positive pressure from positive pressure source 150 to move solution from solution source 145 to tissue interface 135, as indicated at 2215. Alternatively or additionally, solution source 145 may be raised to a height sufficient to allow gravity to move the solution into tissue interface 135, as indicated at 2220.
[0185] The controller 120 can also control the hydrodynamics of the infusion (at 2225) by providing a continuous solution flow (at 2230) or an intermittent solution flow (at 2235). Negative pressure can be applied to provide either a continuous or intermittent solution flow (at 2240). The application of negative pressure can be implemented to provide a continuous pressure operating mode (at 2245) to allow a continuous flow of the infusion solution through the tissue interface 135, or to provide a dynamic pressure operating mode (at 2255) to vary the flow rate of the infusion solution through the tissue interface 135. Alternatively, the application of negative pressure can be implemented to provide an intermittent operating mode (at 2260) to allow the infusion solution to remain at the tissue interface 135. In intermittent mode, a specific fill volume and residence time can be provided, depending on, for example, the type of tissue site being treated and the type of dressing used. Negative pressure treatment (at 2265) can be applied after or during the solution infusion. The controller 120 can be used to select the operating mode and the duration of negative pressure therapy before starting another infusion cycle (at 2270) by infusing more solution (at 2205).
[0186] The systems, devices, and methods described herein offer significant advantages. Dressing 110 can be applied to intact skin without the need for resizing and reduces the risk of softening. In some configurations, dressing 110 can remain on the wound for up to seven days with a low risk of ingrown tissue or loss of manifold efficacy. Dressing 110 can be particularly advantageous for treating medium-depth wounds with moderate to high levels of exudate. For example, some wounds, especially those that are highly infected, may produce very viscous exudate, which may reduce the level of negative pressure delivered to the wound site. Perforation 415 can increase the effectiveness of removing exudate through dressing 110. Furthermore, infusion therapy can be used to treat wounds producing thick exudate to treat causal infection, drain exudate from the wound and dressing, or both. Perforation 415 can improve the efficiency of the applied infusion solution for removing exudate from dressing 110 and delivering the solution to the wound.
[0187] Although illustrated in some illustrative embodiments, those skilled in the art will recognize that the systems, apparatuses, and methods described herein are readily adaptable to various changes and modifications falling within the scope of the appended claims. Furthermore, unless the context clearly requires, the use of terms such as “or” to describe different alternatives need not be mutually exclusive, and unless the context clearly requires, the indefinite articles “a” or “an” do not limit the subject matter to a single instance.
[0188] For purposes of sale, manufacture, assembly, or use, certain components can be combined or excluded in various configurations. For example, in some configurations, container 115, controller 120, or other components can be manufactured, configured, assembled, or sold independently of other components. Additionally, some layers, such as third layer 605 and retaining layer 2105, can be combined or excluded from various configurations. For example, retaining layer 2105 can be combined with... Figure 6 Examples can be combined, and examples of patterns and shapes of perforations 415 can be combined with other examples and features.
[0189] The appended claims set forth the novelty and inventive step aspects of the subject matter described above; however, the claims may also cover other subject matter not explicitly enumerated. For example, certain features, elements, or aspects may be omitted from the claims if it is not necessary to distinguish novel and inventive features from those known to a person skilled in the art. Features, elements, and aspects described in the context of some embodiments may also be omitted, combined, or replaced with alternative features for the same, equivalent, or similar purpose without departing from the scope of the invention as defined by the appended claims.
Claims
1. A dressing for treating tissue sites using negative pressure, said dressing comprising: The first layer includes a foam manifold; A second layer adjacent to the first layer, the second layer comprising a polymer membrane having a plurality of fluid channels; A third layer is arranged adjacent to the second layer, the third layer comprising a gel containing a plurality of pores, at least one of the pores being sized such that more than one fluid channel and a portion of the second layer are configured to be exposed through the at least one pore and freely extend across the at least one pore in the third layer. The cover adjacent to the first layer includes a polymer cover fabric, an edge extending beyond the first layer, and an adhesive disposed in the edge, the adhesive being exposed through at least one of the holes in the third layer.
2. The dressing according to claim 1, wherein, The foam manifold comprises a mesh foam.
3. The dressing according to claim 1, wherein, The foam manifold comprises compressed mesh foam.
4. The dressing according to claim 1, wherein, The foam manifold comprises felted mesh foam.
5. The dressing according to claim 1, wherein, The polymer film of the second layer is hydrophobic.
6. The dressing according to claim 5, wherein, The polymer film is a polyethylene film with an area density of less than 30 grams per square meter.
7. The dressing according to claim 1, wherein, The gel in the third layer is a polymer gel with a coating weight of approximately 250 grams per square centimeter.
8. The dressing according to claim 1, wherein, The gel in the third layer is a silicone gel.
9. The dressing according to claim 1, wherein, The third layer of gel comprises a silicone gel with a coating weight of approximately 250 grams per square centimeter.
10. The dressing according to claim 1, wherein, The gel is a silicone, polyurethane, hydrocolloid, or acrylic compound.
11. The dressing according to claim 1, wherein, The first and second layers are enclosed between the third layer and the cover.
12. The dressing of claim 1, further comprising a fluid port coupled to the cover, the fluid port being configured to be coupled to a fluid conductor.
13. The dressing of claim 1, further comprising a retaining layer disposed between the first layer and the cover, wherein, The retaining layer has greater compressibility than the first layer.
14. The dressing according to claim 13, wherein, The retaining layer includes a second manifold arranged adjacent to the foam manifold.
15. The dressing according to claim 13, wherein, The retaining layer comprises open-cell foam.
16. The dressing according to claim 13, wherein, The retaining layer comprises open-cell foam having between 10 and 80 pores per inch.
17. The dressing according to claim 1, wherein, Foam manifolds include variable density.
18. The dressing according to claim 1, wherein, The foam manifold includes at least a first region having a first density and a second region having a second density greater than the first density, wherein the second region is configured to deform less than the first region under negative pressure.
19. The dressing according to claim 18, wherein, The first region includes a first material, and the second region includes a second material.
20. The dressing according to claim 1, wherein, The foam manifold includes a pattern of regions with different densities.
21. A system for treating tissues using negative pressure, the system comprising: Negative pressure source; as well as The dressing according to any one of the preceding claims is fluidly connected to the negative pressure source.
22. The system of claim 21 further includes a drip solution source fluidly connected to the dressing.
